Intent to Sole Source - Biolegend Oliogos

The National Institutes of Health, Clinical Center (NIH-CC) issued solicitation number NOI-CC-OLAO-26-004813 as a notice of intent to negotiate a sole source contract with Biolegend for custom oligos. These products are required by the PACT team at the Clinical Center to conduct single cell copy number analysis using the Tapestri instrument for CAR-T cell products in support of clinical quality control assays. This procurement is classified under NAICS code 325414, Biological Product (except Diagnostic) Manufacturing, and PSC code 6550, IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS.

The government intends to award this requirement on an other than full and open competition basis under the statutory authority of 41 U.S.C. 253(c)(1), as Biolegend is the only responsible source capable of satisfying the agency's needs. There is no set-aside designated for this action, identified by the code and explanation NONE. The primary place of performance is Bethesda, Maryland.

The response deadline for submitting capability statements is May 8, 2026, at 12:00 PM Eastern Standard Time. One attachment, a PDF document titled Quote COLG260327-JM-NIH.pdf, was published with the notice on April 29, 2026. Although this is not a request for proposal, the government will consider all responses received by the closing date to determine whether to compete the requirement.